. 2022 Oct 11;3:1004056. doi: 10.3389/falgy.2022.1004056

Table 5.

Summary of the relative potency ranges and potency ratios of capsule and sachet lots used in ARC003 and ARC010 clinical studies.

Clinical Study	Number of Drug Product Batches	Ara h 1		Ara h 2		Ara h 6
Clinical Study	Number of Drug Product Batches	Potency Range^a	Ratio^b	Potency Range^a	Ratio^b	Potency Range^a	Ratio^b
PALISADE^c (ARC003)	8	0.68–1.59	2.34	0.72–1.34	1.86	0.63–1.26	2.00
ARTEMIS^d (ARC010)	11	0.68–1.25	1.83	0.93–1.34	1.44	0.75–1.26	1.68
Total	19	0.68–1.59	2.34	0.72–1.34	1.86	0.63–1.26	2.00

The data shown in the table are from a total of 5,246 individual up-dosing events for 520 patients.

^{^a}

Relative to the reference standard.

^{^b}

Ratio is from highest to lowest potency.

^{^c}

PALISADE: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization (22).

^{^d}

ARTEMIS: AR101 Trial in Europe Measuring Oral Immunotherapy Success (23).